RGC

Regencell Bioscience Holdings Limited

$5.23

-7.02%

Regencell Bioscience Holdings Limited focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, TCM brain theory, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Source: Yahoo Finance
AI summary

Price & performance

1M-9.8%
3M+0.3%
YTD-70.1%
1Y-54.6%
52-week range—
Beta0.12
Full chart and returns against a benchmark

Q-Score

62/ 100

Quality against peers; 50 is the peer median.

Growth96
Risk28
Performance84
Valuation37
Profitability39
Leverage76
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2026

Revenue—
Net income-$11.7M
Net margin—
Historical fundamentals

Red flags in filings

2active red flags
Going-concern doubtOct 7, 2026
Material weakness in controlsOct 7, 2026
Filings, findings and the timeline

Valuation

RGCIndustryP/E—35.25P/S—2.74EV/EBITDA—16.35P/B194.282.46PEG—0.87
Dividend yield0.00%
Every valuation metric

Earnings

Oct 28next report
EPS estimate—
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate